British scientists have created human embryos containing DNA from two women and one man, a procedure that could potentially prevent conditions including epilepsy, diabetes and heart failure. Though the preliminary research has raised concerns about the possibility of genetically modified babies, the scientists say that the embryos are still only primarily the product of one man and one woman. "We are not trying to alter genes, we're just trying to swap a small proportion of the bad ones for some good ones," said Patrick Chinnery, a professor of neurogenetics at Newcastle University involved in the research.

The process aims to avoid passing onto children bad mitochondria genes, which are contained outside the nucleus in a normal female egg. Mitochondria are a cell's energy source, but mistakes in their genetic code can result in serious diseases like epilepsy, strokes, and mental retardation.

In their research, Chinnery and colleagues used normal embryos created from one man and one woman that had defective mitochondria in the woman's egg. They then transplanted that embryo into an emptied egg donated from a second woman who had healthy mitochondria.

"The proportion of genes in the mitochondria is infinitesimal," said Francoise Shenfield, a fertility expert with the European Society of Human Fertility and Reproduction. Shenfield is not connected to the Newcastle University Research.

Only trace amounts of a person's genes come from the mitochondria, and experts said it would be incorrect to say that the embryos have three parents.

"Most of the genes that make you who you are are inside the nucleus," Chinnery said. "We're not going anywhere near that."

So far, 10 such embryos have been created, though they have not been allowed to develop for more than five days. Chinnery hoped that after further experiments in the next few years the process might be available to parents undergoing in-vitro fertilization.

Similar research has been conducted in animals in Japan, and has already led to the birth of healthy mice who had their mitochondria genes corrected.

Shenfield said that further tests to assess the safety and efficacy of the process were necessary before it could be offered as a potential treatment.